BOLT

Investor Moves

Name	Value	Action	Change	Price	Last Price
Jim SimonsRenaissance Technologies $312k77.2k shares AddQ1 2026 $11k $4.04 $4.42
Jim SimonsRenaissance Technologies $148.6K AddQ4 2025 $149k -- $4.42

News

accessnewswire.comBolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Projectaccessnewswire.comJun 12

zacks.comBolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 12

globenewswire.comBolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 12

defenseworld.netShort Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Grows By 355.3%defenseworld.netApr 27

Trade BOLT

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.

CEO: William Quinn
IPO Date: Feb 5, 2021

Market Data

Open: $4.30
High: $4.59
Low: $3.99
Volume: 67.8K
Avg Volume: 26.8K
52W High: $7.20
52W Low: $3.91

Valuation

Market Cap: $7.7M
Enterprise Value: $18.4M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$39.9M
Revenue: $7.7M
Net Income: -$33.4M
Cash: $11.7M
Debt: $23M

Events

EarningsAug 13

EPS est. -3.38667